ifosfamide has been researched along with Carcinosarcoma in 41 studies
Carcinosarcoma: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)." | 9.51 | Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022) |
| "To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity." | 9.12 | Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007) |
| "To determine progression-free survival (PFS) and overall survival (OS) in women with completely resected stage I or II carcinosarcoma of the uterus treated with adjuvant ifosfamide and cisplatin, and to assess the toxicity of this regimen." | 9.11 | Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005) |
| "The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival." | 9.09 | A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000) |
| "This study aimed to retrospectively evaluate the efficacy and safety of ifosfamide plus paclitaxel(IT)in Japanese patients with recurrent or metastatic uterine carcinosarcoma." | 7.91 | [Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma]. ( Fujiwara, Y; Ishikawa, M; Kato, T; Kojima, Y; Nishikawa, T; Noguchi, E; Ohtake, Y; Okuma, H; Seo, T; Shimomura, A; Sudo, K; Tamura, K; Tanioka, M; Uehara, T; Uno, M; Yonemori, K, 2019) |
| "A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 7.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
| "To describe a patient with ifosfamide-induced nonconvulsive status epilepticus." | 7.69 | Ifosfamide-induced nonconvulsive status epilepticus. ( Badesha, PS; Bhardwaj, A, 1995) |
| "This phase III randomized trial (NCT00954174) tested the null hypothesis that paclitaxel and carboplatin (PC) is inferior to paclitaxel and ifosfamide (PI) for treating uterine carcinosarcoma (UCS)." | 5.51 | Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. ( Copeland, LJ; DiSilvestro, PA; Filiaci, VL; Hensley, ML; Huang, HQ; Ioffe, OB; Miller, DS; Moore, KN; Mutch, DG; Powell, MA; Santin, A; Secord, AA; Spirtos, NM; Tewari, KS; Warshal, DP, 2022) |
| "MAID chemotherapy may be useful in the treatment of carcinosarcoma of the ovary." | 5.28 | Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. ( Shackney, S; Simon, SR; Uhl, M; Wang, SE, 1991) |
| " Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1." | 5.25 | [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a ( Ardenne, M; Reitnauer, PG, 1975) |
| "To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity." | 5.12 | Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. ( Bitterman, P; Eaton, L; Filiaci, V; Homesley, HD; Kilgore, LC; Markman, M; Monk, BJ; Ueland, FR, 2007) |
| "To determine progression-free survival (PFS) and overall survival (OS) in women with completely resected stage I or II carcinosarcoma of the uterus treated with adjuvant ifosfamide and cisplatin, and to assess the toxicity of this regimen." | 5.11 | Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. ( Carson, LF; Gallion, H; Kauderer, J; Lentz, SS; Sutton, G; Whitney, CW, 2005) |
| "The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival." | 5.09 | A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. ( Brunetto, VL; Hsiu, JG; Kilgore, L; Lentz, SS; McGehee, R; Olt, G; Soper, JT; Sorosky, J; Sutton, G, 2000) |
| "We present a patient with peritoneal carcinosarcoma who was treated with the alkylating agent ifosfamide and experienced a rapid decline in mental status." | 4.90 | Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature. ( Friedman, D; Racela, R; Taupin, D, 2014) |
| "In advanced stage metastatic uterine carcinosarcoma as well as recurrent disease adjuvant combination, chemotherapy with ifosfamide should be considered." | 4.89 | Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Das, N; Galaal, K; Godfrey, K; Kucukmetin, A; Lopes, AD; Naik, R; van der Heijden, E, 2013) |
| " In the primary treatment/ first line therapy of advanced stage metastatic uterine carcinosarcoma, as well as in recurrent disease, adjuvant combination chemotherapy with ifosfamide and paclitaxel should be considered." | 4.87 | Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. ( Bryant, A; Galaal, K; Godfrey, K; Kucukmetin, A; Naik, R, 2011) |
| "In summary, in our cohort of ovarian carcinosarcoma patients, median PFS is longer in patients treated with carboplatin/paclitaxel compared to ifosfamide/paclitaxel." | 3.88 | Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature. ( Brackmann, M; Erba, J; McLean, K; Reynolds, RK; Stasenko, M; Uppal, S, 2018) |
| "A retrospective study to evaluate six cycles of cisplatin 40 mg/m2 on day 1 and ifosfamide 1,200 mg/m2 daily on days 1 to 4 with Mesna every four weeks as first line treatment for 29 patients with a diagnosis of uterine carcinosarcoma." | 3.83 | Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma. ( Abu-Khalaf, MM; Azodi, M; Hatzis, C; Higgins, S; Lin, K; Ratner, E; Raza, MA; Rutherford, TJ; Santin, AD; Schwartz, PE; Silasi, DA; Wang, H, 2016) |
| "Our study corroborates GOG 150 results, and shows that paclitaxel-carboplatin appears to be an efficacious adjuvant chemotherapy regimen for completely resected uterine carcinosarcoma." | 3.74 | A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma. ( Abu-Rustum, NR; Aghajanian, CA; Alektiar, KM; Hensley, ML; Iasonos, A; Makker, V; Zhou, Q, 2008) |
| "To describe a patient with ifosfamide-induced nonconvulsive status epilepticus." | 3.69 | Ifosfamide-induced nonconvulsive status epilepticus. ( Badesha, PS; Bhardwaj, A, 1995) |
| "Carcinosarcoma is a rare cancer, and its prognosis is poor." | 1.56 | Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. ( Ebata, T; Fujiwara, K; Fujiwara, Y; Hasegawa, K; Kato, T; Nishikawa, T; Noguchi, E; Shimomura, A; Sudo, K; Tamura, K; Yonemori, K, 2020) |
| "Cervical carcinosarcomas are rare neoplasms; optimal treatment is unclear." | 1.34 | Carcinosarcoma of the uterine cervix: case report and discussion. ( Bolis, P; Donadello, N; Formenti, G; Ghezzi, F; Laterza, R; Mellana, L; Riva, C; Seveso, A; Zefiro, F, 2007) |
| "Ovarian carcinosarcoma has a poor overall prognosis with median survival rates reported in the literature ranging from 7-10 months." | 1.33 | Carcinosarcoma of the ovary-a case series. ( Gold, MA; Huh, WK; Johnson, GA; Lewin, SN; Mannel, RS; McMeekin, DS; Mutch, DG; Powell, MA; Rutledge, TL; Walker, JL, 2006) |
| "MAID chemotherapy may be useful in the treatment of carcinosarcoma of the ovary." | 1.28 | Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine. ( Shackney, S; Simon, SR; Uhl, M; Wang, SE, 1991) |
| "The ANH-nephroblastoma, however, could not be cured even with the highest tolerable doses of ifosfamide." | 1.26 | [Chemotherapeutic activity of ifosfamide in 6 different isologously transplanted experimental tumours of BD-rats (author's transl)]. ( Stekar, J, 1976) |
| " Experiments in 214 DS carcinosarcoma bearing Wistar rats have shown that BA 1, at a dosage of only about 12 percent LD50 (150 mg kg) and negligible lethality (1." | 1.25 | [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a ( Ardenne, M; Reitnauer, PG, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (12.20) | 18.7374 |
| 1990's | 3 (7.32) | 18.2507 |
| 2000's | 13 (31.71) | 29.6817 |
| 2010's | 16 (39.02) | 24.3611 |
| 2020's | 4 (9.76) | 2.80 |
| Authors | Studies |
|---|---|
| Powell, MA | 2 |
| Filiaci, VL | 1 |
| Hensley, ML | 2 |
| Huang, HQ | 1 |
| Moore, KN | 1 |
| Tewari, KS | 1 |
| Copeland, LJ | 1 |
| Secord, AA | 2 |
| Mutch, DG | 2 |
| Santin, A | 1 |
| Warshal, DP | 1 |
| Spirtos, NM | 1 |
| DiSilvestro, PA | 1 |
| Ioffe, OB | 2 |
| Miller, DS | 1 |
| Yang, ST | 1 |
| Wang, PH | 1 |
| Li, J | 1 |
| Wang, S | 1 |
| Tang, X | 1 |
| Que, L | 1 |
| Han, W | 1 |
| Yu, B | 1 |
| Ohtake, Y | 1 |
| Sudo, K | 2 |
| Kojima, Y | 1 |
| Seo, T | 1 |
| Okuma, H | 1 |
| Nishikawa, T | 3 |
| Uno, M | 1 |
| Uehara, T | 1 |
| Ishikawa, M | 1 |
| Tanioka, M | 1 |
| Noguchi, E | 2 |
| Shimomura, A | 2 |
| Yonemori, K | 2 |
| Kato, T | 2 |
| Fujiwara, Y | 2 |
| Tamura, K | 2 |
| Ebata, T | 1 |
| Hasegawa, K | 2 |
| Fujiwara, K | 4 |
| Brackmann, M | 1 |
| Stasenko, M | 1 |
| Uppal, S | 1 |
| Erba, J | 1 |
| Reynolds, RK | 1 |
| McLean, K | 1 |
| Kurita, D | 1 |
| Mokuno, Y | 1 |
| Matsubara, H | 1 |
| Kaneko, H | 1 |
| Shamoto, M | 1 |
| Satou, A | 1 |
| Iyomasa, S | 1 |
| Galaal, K | 2 |
| van der Heijden, E | 1 |
| Godfrey, K | 2 |
| Naik, R | 2 |
| Kucukmetin, A | 2 |
| Bryant, A | 2 |
| Das, N | 1 |
| Lopes, AD | 1 |
| Taupin, D | 1 |
| Racela, R | 1 |
| Friedman, D | 1 |
| Lorusso, D | 1 |
| Martinelli, F | 1 |
| Mancini, M | 1 |
| Sarno, I | 1 |
| Ditto, A | 1 |
| Raspagliesi, F | 1 |
| Dandamudi, RK | 1 |
| Aslam, S | 1 |
| Walji, N | 1 |
| El-Modir, A | 1 |
| Fernando, I | 1 |
| Dickson, EL | 1 |
| Vogel, RI | 1 |
| Gehrig, PA | 1 |
| Pierce, S | 1 |
| Havrilesky, L | 1 |
| Dottino, J | 1 |
| Fader, AN | 1 |
| Ricci, S | 1 |
| Geller, MA | 1 |
| Matsuo, K | 1 |
| Takazawa, Y | 1 |
| Ross, MS | 1 |
| Elishaev, E | 1 |
| Podzielinski, I | 1 |
| Yunokawa, M | 1 |
| Sheridan, TB | 1 |
| Bush, SH | 1 |
| Klobocista, MM | 1 |
| Blake, EA | 1 |
| Takano, T | 1 |
| Matsuzaki, S | 1 |
| Baba, T | 1 |
| Satoh, S | 1 |
| Shida, M | 1 |
| Ikeda, Y | 1 |
| Adachi, S | 1 |
| Yokoyama, T | 1 |
| Takekuma, M | 1 |
| Hazama, Y | 1 |
| Kadogami, D | 1 |
| Moffitt, MN | 1 |
| Takeuchi, S | 1 |
| Nishimura, M | 1 |
| Iwasaki, K | 1 |
| Ushioda, N | 1 |
| Johnson, MS | 1 |
| Yoshida, M | 1 |
| Hakam, A | 1 |
| Li, SW | 1 |
| Richmond, AM | 1 |
| Machida, H | 1 |
| Mhawech-Fauceglia, P | 1 |
| Ueda, Y | 1 |
| Yoshino, K | 2 |
| Yamaguchi, K | 1 |
| Oishi, T | 1 |
| Kajiwara, H | 1 |
| Yasuda, M | 1 |
| Kawana, K | 1 |
| Suda, K | 1 |
| Miyake, TM | 1 |
| Moriya, T | 1 |
| Yuba, Y | 1 |
| Morgan, T | 1 |
| Fukagawa, T | 1 |
| Wakatsuki, A | 1 |
| Sugiyama, T | 1 |
| Pejovic, T | 1 |
| Nagano, T | 1 |
| Shimoya, K | 1 |
| Andoh, M | 1 |
| Shiki, Y | 1 |
| Enomoto, T | 1 |
| Sasaki, T | 1 |
| Mikami, M | 1 |
| Shimada, M | 1 |
| Konishi, I | 1 |
| Kimura, T | 1 |
| Post, MD | 1 |
| Shahzad, MM | 1 |
| Im, DD | 1 |
| Yoshida, H | 1 |
| Omatsu, K | 1 |
| Ueland, FR | 2 |
| Kelley, JL | 1 |
| Karabakhtsian, RG | 1 |
| Roman, LD | 1 |
| Abu-Khalaf, MM | 1 |
| Raza, MA | 1 |
| Hatzis, C | 1 |
| Wang, H | 1 |
| Lin, K | 1 |
| Higgins, S | 1 |
| Ratner, E | 1 |
| Silasi, DA | 1 |
| Azodi, M | 1 |
| Rutherford, TJ | 1 |
| Santin, AD | 1 |
| Schwartz, PE | 1 |
| Higgins, SC | 1 |
| Zakashansky, K | 1 |
| Bovbjerg, DH | 1 |
| Hagopian, G | 1 |
| Makker, V | 1 |
| Abu-Rustum, NR | 1 |
| Alektiar, KM | 1 |
| Aghajanian, CA | 1 |
| Zhou, Q | 1 |
| Iasonos, A | 1 |
| Okazawa, M | 1 |
| Masuhara, K | 1 |
| Miyoshi, A | 1 |
| Ohta, Y | 1 |
| Kamiura, S | 1 |
| Tomita, Y | 1 |
| Xu, C | 1 |
| Nishi, H | 1 |
| Isaka, K | 1 |
| Loizzi, V | 1 |
| Cormio, G | 2 |
| Camporeale, A | 1 |
| Falagario, M | 1 |
| De Mitri, P | 1 |
| Scardigno, D | 1 |
| Putignano, G | 1 |
| Selvaggi, LE | 1 |
| Einstein, MH | 1 |
| Klobocista, M | 1 |
| Hou, JY | 1 |
| Lee, S | 1 |
| Mutyala, S | 1 |
| Mehta, K | 1 |
| Reimers, LL | 1 |
| Kuo, DY | 1 |
| Huang, GS | 1 |
| Goldberg, GL | 1 |
| Chang, CC | 1 |
| Wu, CC | 1 |
| Saint-Georges, F | 1 |
| Terrier, P | 1 |
| Sabourin, JC | 1 |
| Bonvalot, S | 1 |
| De Montpreville, V | 1 |
| Ruffie, P | 1 |
| van Rijswijk, RE | 1 |
| Vermorken, JB | 1 |
| Reed, N | 1 |
| Favalli, G | 1 |
| Mendiola, C | 1 |
| Zanaboni, F | 1 |
| Mangili, G | 1 |
| Vergote, I | 1 |
| Guastalla, JP | 1 |
| ten Bokkel Huinink, WW | 1 |
| Lacave, AJ | 1 |
| Bonnefoi, H | 1 |
| Tumulo, S | 1 |
| Rietbroek, R | 1 |
| Teodorovic, I | 1 |
| Coens, C | 1 |
| Pecorelli, S | 1 |
| Sutton, G | 2 |
| Kauderer, J | 1 |
| Carson, LF | 1 |
| Lentz, SS | 2 |
| Whitney, CW | 1 |
| Gallion, H | 1 |
| Rutledge, TL | 1 |
| Gold, MA | 1 |
| McMeekin, DS | 1 |
| Huh, WK | 1 |
| Lewin, SN | 1 |
| Johnson, GA | 1 |
| Walker, JL | 1 |
| Mannel, RS | 2 |
| Nitsche, M | 1 |
| Hermann, RM | 1 |
| Christiansen, H | 1 |
| Berger, J | 1 |
| Pradier, O | 1 |
| Homesley, HD | 1 |
| Filiaci, V | 1 |
| Markman, M | 1 |
| Bitterman, P | 1 |
| Eaton, L | 1 |
| Kilgore, LC | 1 |
| Monk, BJ | 1 |
| Laterza, R | 1 |
| Seveso, A | 1 |
| Zefiro, F | 1 |
| Formenti, G | 1 |
| Mellana, L | 1 |
| Donadello, N | 1 |
| Ghezzi, F | 1 |
| Bolis, P | 1 |
| Riva, C | 1 |
| Wolfson, AH | 1 |
| Brady, MF | 1 |
| Rocereto, T | 1 |
| Lee, YC | 1 |
| Futoran, RJ | 1 |
| Cohn, DE | 1 |
| Ramondetta, LM | 1 |
| Jhingran, A | 1 |
| Bhardwaj, A | 1 |
| Badesha, PS | 1 |
| Melilli, GA | 1 |
| Di Vagno, G | 1 |
| Greco, P | 1 |
| Fontana, A | 1 |
| Carriero, C | 1 |
| Loverro, G | 1 |
| Selvaggi, L | 1 |
| Edmonson, JH | 1 |
| Brunetto, VL | 1 |
| Kilgore, L | 1 |
| Soper, JT | 1 |
| McGehee, R | 1 |
| Olt, G | 1 |
| Sorosky, J | 1 |
| Hsiu, JG | 1 |
| Ardenne, M | 1 |
| Reitnauer, PG | 3 |
| von Ardenne, M | 2 |
| Brock, N | 1 |
| Stekar, J | 2 |
| Pohl, J | 1 |
| Simon, SR | 1 |
| Wang, SE | 1 |
| Uhl, M | 1 |
| Shackney, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, P[NCT00954174] | Phase 3 | 637 participants (Actual) | Interventional | 2009-08-17 | Active, not recruiting | ||
| Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)[NCT02993705] | Phase 2 | 45 participants (Actual) | Interventional | 2017-02-22 | Completed | ||
| "A Pilot Phase II Trial of Adjuvant Radiation Therapy Sandwiched Between Ifosfamide in Patients With Mixed Mesodermal Tumors"[NCT00231842] | Phase 2 | 30 participants (Actual) | Interventional | 2003-02-28 | Completed | ||
| A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus[NCT00003128] | Phase 3 | 166 participants (Anticipated) | Interventional | 1997-11-30 | Completed | ||
| A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus[NCT00002546] | Phase 3 | 216 participants (Anticipated) | Interventional | 1993-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured in months from randomization to last contact or the earlier of the date of progression or death. (NCT00954174)
Timeframe: Approximately 9 years and 7 months
| Intervention | months (Median) |
|---|---|
| Regimen I - Uterine Carcinsarcoma Subjects | 16.3 |
| Regimen II - Uterine Carcinsarcoma Subjects | 11.7 |
| Regimen III - Non-uterine Carcinsarcoma Subjects | 14.6 |
| Regimen IV - Non-uterine Carcinsarcoma Subjects | 10.3 |
Measured in months from randomization to last contact or death. Primary analysis was restricted to the eligible uterine carcinosarcoma cohort. (NCT00954174)
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 115 months.
| Intervention | months (Median) |
|---|---|
| Regimen I- Uterine Carcinsarcoma Subjects | 37.3 |
| Regimen II - Uterine Carcinsarcoma Subjects | 29 |
Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). . The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline (Pre cycle 1)
| Intervention | units on a scale-baseline (Mean) |
|---|---|
| Regimen I - Uterine and Non-Uterine Subjects | 40.2 |
| Regimen II - Uterine and Non-Uterine Subjects | 41.0 |
Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Baseline - Prior to study treatment
| Intervention | units on a scale (time point) (Mean) |
|---|---|
| Regimen I - Uterine and Non-Uterine Subjects | 96.2 |
| Regimen II - Uterine and Non-Uterine Subjects | 97.5 |
Maximum grade experienced among all treated and eligible patients. The grades are described by severity. Grade 1 is the lowest (most mild) and Grade 5 being death (most severe). Adverse events were analyzed across cohorts since disease site was considered independent of AEs. (NCT00954174)
Timeframe: Patients were assessed for adverse events during active protocol treatment and up to 30 days after the last cycle of treatment on the protocol.
| Intervention | Participants (Count of Participants) | ||||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 5 | |
| Regimen I - Uterine and Non-Uterine Subjects | 3 | 22 | 107 | 130 | 6 |
| Regimen II - All Uterine and Non-Uterine Subjects | 3 | 80 | 97 | 61 | 3 |
Patient reported quality of life was measured with the Treatment Outcome Index (TOI) of the Functional Assessment of Cancer Therapy for endometrial cancer (FACT-En TOI). The FACT-En TOI is a scale for assessing general QOL of endometrial cancer patients. The FACT-En TOI score ranges 0-120 with a large score suggesting better QOL. Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1.
| Intervention | units on a scale (time point) (Least Squares Mean) | ||
|---|---|---|---|
| Pre-cycle 3 | Pree-cycle 6 | 30 weeks post cycle 1 | |
| Regimen I - Uterine and Non-Uterine Subjects | 93.3 | 91.6 | 98.0 |
| Regimen II - Uterine and Non-Uterine Subjects | 93.3 | 91.6 | 97.6 |
Patient reported peripheral neuropathy symptoms was measured with the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity subscale (short version) (FACT/GOG-Ntx subscale). The FACT/GOG-Ntx subscale contains 11 items. Each item was scored using a 5-point scale (0=not at all; 1=a little bit; 2=somewhat; 3=quite a bit; 4=very much). The Ntx score ranges 0-44 with a large score suggesting less peripheral neuropathy symptoms.Quality of Life was analyzed across cohorts since disease site was considered independent of Quality of Life. (NCT00954174)
Timeframe: Prior to cycle 3, Prior to cycle 6, 30 weeks post cycle 1
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Prior to cycle 3 | Prior to cycle 6 | 30 weeks post cycle 1 | |
| Regimen I - Uterine and Non-Uterine Subjects | 37.2 | 34.1 | 34.8 |
| Regimen II - Uterine and Non-Uterine Subjects | 37.0 | 34.2 | 34.9 |
Out of 162 planned cycles, a total of 138 cycles (85%) were administered. Number of cycles during which participants with grades 3 and 4 experienced hematologic toxicities are reported. Most of the toxicities were self-limiting. (NCT00231842)
Timeframe: 2 years
| Intervention | Cycles (Number) | ||
|---|---|---|---|
| Neutropenia | Anemia | Thrombocytopenia | |
| Grade 3 Toxicity | 11 | 6 | 6 |
| Grade 4 Toxicity | 14 | 0 | 2 |
6 reviews available for ifosfamide and Carcinosarcoma
| Article | Year |
|---|---|
Primary maxillary sinus carcinosarcoma with multidisciplinary management: a case report with 4 years follow-up and literature review.
Topics: Adult; Carcinosarcoma; Doxorubicin; Female; Follow-Up Studies; Humans; Ifosfamide; Maxillary Sinus; | 2023 |
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid | 2013 |
Ifosfamide chemotherapy and nonconvulsive status epilepticus: case report and review of the literature.
Topics: Carcinosarcoma; Cerebral Cortex; Diagnosis, Differential; Electroencephalography; Epilepsy, Generali | 2014 |
Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma.
Topics: Antineoplastic Agents, Alkylating; Carcinosarcoma; Chemotherapy, Adjuvant; Female; Humans; Ifosfamid | 2011 |
Carcinosarcoma of the ovary: analysis of 13 cases and review of the literature.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; CA-19-9 Antigen; Carboplatin; | 2011 |
[Chemotherapy in the treatment of ovarian carcinosarcoma].
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemot | 1999 |
7 trials available for ifosfamide and Carcinosarcoma
| Article | Year |
|---|---|
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Disease-Free Sur | 2022 |
Phase II trial of adjuvant pelvic radiation "sandwiched" between ifosfamide or ifosfamide plus cisplatin in women with uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2012 |
Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Doxorubicin; | 2003 |
Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chem | 2005 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antin | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherap | 2007 |
A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemother | 2000 |
28 other studies available for ifosfamide and Carcinosarcoma
| Article | Year |
|---|---|
Abandon ifosfamide-based regimen and use paclitaxel-carboplatin regimen for the treatment of uterine carcinosarcoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Female; Humans; Ifosfam | 2022 |
[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Disease-Free Survival; Female; Human | 2019 |
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Docetaxel; | 2020 |
Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2018 |
Primary hepatic carcinosarcoma with multimodal treatment.
Topics: Aged; Antibiotics, Antineoplastic; Carcinosarcoma; Combined Modality Therapy; Doxorubicin; Humans; I | 2018 |
Carboplatin-Paclitaxel versus Cisplatin-Ifosfamide in the treatment of uterine carcinosarcoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2014 |
Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma | 2015 |
A multi-institutional study of outcomes in stage I-III uterine carcinosarcoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma | 2015 |
Significance of histologic pattern of carcinoma and sarcoma components on survival outcomes of uterine carcinosarcoma.
Topics: Adult; Aged; Carcinoma; Carcinosarcoma; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Human | 2016 |
Efficacy and tolerability of combination cisplatin and ifosfamide chemotherapy with vaginal cuff brachytherapy in the first line treatment of uterine carcinosarcoma.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Brachytherap | 2016 |
Unexpected vomiting in a woman contemplating a second course of chemotherapy for carcinosarcoma of the uterus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; F | 2008 |
A retrospective assessment of outcomes of chemotherapy-based versus radiation-only adjuvant treatment for completely resected stage I-IV uterine carcinosarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinosarcoma; Cisplatin; Diseas | 2008 |
A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinosarcoma; Endometrium; Female; Humans; | 2011 |
A case of uterine cervical carcinosarcoma recurrence who obtained a clinically complete response by ifosfamide, doxorubicin and cisplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Doxorubicin; Female; Huma | 2011 |
Beau's lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Female; Humans; Ifosfamide; Middle A | 2013 |
[Pulmonary carcinosarcoma with jejunal metastasis: complete response to chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Doxorubicin; Humans; Ifos | 2002 |
Carcinosarcoma of the ovary-a case series.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcino | 2006 |
Rationale for individualized therapy in Sinonasal Teratocarcinosarcoma (SNTC): case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Combined Modality | 2005 |
Carcinosarcoma of the uterine cervix: case report and discussion.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; | 2007 |
Eleven years: the long and winding road.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Chemotherapy, Adjuvant; Cisplatin; C | 2007 |
Ifosfamide-induced nonconvulsive status epilepticus.
Topics: Aged; Antineoplastic Agents, Alkylating; Carcinosarcoma; Female; Genital Neoplasms, Female; Humans; | 1995 |
Are we there yet?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Cisplatin; Female; Humans; Ifosfamid | 2000 |
[Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a
Topics: Animals; Antineoplastic Agents; Carcinosarcoma; Cyclophosphamide; Drug Evaluation, Preclinical; Drug | 1975 |
[The time lapse of the cytostatic effect of ifosfamide].
Topics: Animals; Carcinosarcoma; Cell Survival; Cyclophosphamide; Glucose; Glycolysis; Hydrogen-Ion Concentr | 1978 |
[Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].
Topics: Animals; Antidotes; Carcinosarcoma; Cyclophosphamide; Ifosfamide; Mercaptoethanol; Mesna; Phosphoram | 1979 |
[Chemotherapeutic activity of ifosfamide in 6 different isologously transplanted experimental tumours of BD-rats (author's transl)].
Topics: Animals; Carcinosarcoma; Cyclophosphamide; Female; Ifosfamide; Male; Neoplasms, Experimental; Rats; | 1976 |
[Treatment of the DS-carcinosarcoma in the rat with ifosfamide/dimethylsulfoxide].
Topics: Animals; Carcinosarcoma; Cyclophosphamide; Dimethyl Sulfoxide; Dose-Response Relationship, Drug; Dru | 1975 |
Complete response of carcinosarcoma of the ovary to therapy with doxorubicin, ifosfamide, and dacarbazine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinosarcoma; Combined Modality Therapy; Dacarbazi | 1991 |